Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

OneKidney is developing a renal replacement platform based on a proprietary membrane architecture. The technology is being advanced through a staged development pathway, beginning with extracorporeal and wearable applications and progressing toward a fully implantable artificial kidney, with the core membrane engineered to increase effective surface area and enable continuous solute transport across all phases.

SeeTreat Medical is a software company developing ART.1, an automated decision-support platform for adaptive radiotherapy. The Software as a Medical Device (SaMD) continuously analyzes daily volumetric imaging to track anatomical changes and calculate delivered radiation doses, instantly alerting clinical teams if a patient's treatment plan needs adjustment. Differentiated by its ability to integrate seamlessly with existing linear accelerators without requiring hardware upgrades, SeeTreat enables oncology clinics to efficiently provide personalized, precision cancer treatments.

Arctx Medical, a clinical-stage medical technology company, is developing the world’s first targeted treatment for Acute Pancreatitis (AP). Local cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, localized, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. The company has also received FDA marketing authorization for use of the ACC in patient temperature management, a second and mature market for its technology.

Control Bionics’ NeuroStrip and broader neurotechnology platform use surface electromyography (sEMG) to detect and interpret muscle activation signals, enabling real-time analysis of neuromuscular function. The platform integrates hardware and software to capture, process, and structure physiological data for applications in rehabilitation, assistive technology, and sports and human performance. It is already in use in the US, Europe, Australia and Japan.

Meticuly is the only company with US FDA clearance for 3D-printed titanium patient-specific cranial mesh. Using AI-driven surgical planning software and precision additive manufacturing, Meticuly produces custom cranial implants that deliver superior anatomical fit and clinical outcomes compared to conventional alternatives.

Nami Surgical has developed the world’s first miniaturized ultrasonic scalpel designed specifically for robotic-assisted surgery and the only ultrasonic technology engineered to articulate through wristed robotic joints. This represents a major unmet need in robotic surgery, where ultrasonic energy solutions remain constrained by size, articulation, and integration limitations.

Luminoma is developing the LumAssure, a non-invasive point-and-click device that indicates whether a skin lesion is malignant or benign within seconds. The diagnostic-aid provides clinicians with assurance in their biopsy decision without having to wait days for a lab result. The LumAssure's high accuracy promises to avoid missing cancers and reduce unnecessary procedures and referrals, making clinics more efficient whilst improving patient outcomes.

Pioneers of radar based, ambient health monitoring. Their XK300 sensor is FDA cleared in 6 countries, including the U.S. where they collected 2,750 years' worth of data from 44,000 unique patients to date. Equipped with unique biometric data from patterns of vibrations (breathing/heart), the company was able to create AI models that accurately predicted UTI, Heart Failure, COVID, COPD and even death at 74%~89% accuracy, 4-6 days prior to an event.

CardioStory is a clinical-stage medical technology company developing a Non-Invasive Filling Pressure (NIFP) measurement device for Heart Failure (HF) patients. The system utilizes proprietary fiber optic sensors and advanced algorithms to capture microscopic chest vibrations and accurately calculate pressure inside the heart in just two minutes. Differentiated by its ability to replace highly invasive catheters and surgical implants with a simple, non-invasive assessment, CardioStory aims to empower proactive heart failure management and significantly reduce costly hospital readmissions.

Cytophenix Pty Ltd is an early-stage medical diagnostics company developing FloCAST, an AI-powered platform for rapid Antimicrobial Susceptibility Testing (AST). The technology uses flow cytometry and machine learning to analyze how individual bacterial and fungal cells respond to antibiotics in real-time, delivering targeted treatment recommendations in three to four hours rather than days. Differentiated by its speed, single-cell resolution, and seamless laboratory integration, Cytophenix empowers doctors to treat sepsis more effectively, saving lives while combating global antibiotic resistance.

Navier Medical offers Mosaic, an FDA-cleared, AI-driven software platform for the advanced evaluation of cardiovascular disease from standard CT angiography scans. The technology provides comprehensive 3D visualization and quantifies high-risk arterial plaque burden, allowing clinicians to detect hidden disease often missed by routine assessments. Differentiated by its ability to uncover deep, patient-specific cardiovascular risks without altering the standard imaging workflow, Navier Medical aims to prevent severe cardiac events through earlier, more personalized intervention.

HealthBook+ is a clinical intelligence platform that surfaces actionable insights and guides people in their health. At the center of HealthBook+ is PaiGE, the Agentic Medical Partner, which analyzes medical records and lifestyle data to identify clinically relevant signals and support decision-making across care delivery, care navigation, and employer-sponsored health programs. The platform reduces time spent gathering and reviewing data, enabling clinicians to focus more on patient care.

Spinol advances a new standard in annular repair.OctaSeal™ is a best-in-class, intradiscal annular closure technology—minimally invasive, tissue-preserving, and supported by five-year clinical data—addressing a ~$3B market with only one existing competitor. Visit website. https://spinolmed.com/

Hygea, as the No.1 Chinese Co-ablation developer had developed a strong pipeline in minimally Invasive Oncology area including 85℃/-196℃ Co-Ablation(FDA/CE/CFDA), Irreversible Electroporation(IRE), Microwave Ablation (MWA, FDA/CE/CFDA) systems and TACE Biodegradable Microspheres, based on its percutaneous ablation and Endovascular intervention platforms. More than 30K+ patients globally benefit from company’s innovation since its 1st Co-ablation system launched in 2017.